Get the Stockscreener App
3.98
9.19%
0.335
After Hours:
3.40
-0.58
-14.57%
Conexeu Sciences Inc stock is traded at $3.98, with a volume of 579.70K.
It is up +9.19% in the last 24 hours and down -10.56% over the past month.
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.
See More
Previous Close:
$3.645
Open:
$3.66
24h Volume:
579.70K
Relative Volume:
1.69
Market Cap:
$112.26M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
+15.36%
1M Performance:
-10.56%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.40
$4.05
1-Week Range:
$3.30
$4.36
52-Week Range:
$3.0501
$18.79
Conexeu Sciences Inc Stock (CNXU) Company Profile
Name
Conexeu Sciences Inc
Sector
Industry
Phone
604-315-4722
Address
50 WEST LIBERTY STREET, SUITE 880, RENO
Compare CNXU vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNXU
Conexeu Sciences Inc
|
3.98 | 112.26M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Conexeu Sciences Inc Stock (CNXU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-26 | Initiated | H.C. Wainwright | Buy |
Conexeu Sciences Inc Stock (CNXU) Latest News
Form 4 Conexeu Sciences Inc. For: 28 September By Investing.com - Investing.com India
Form 4 Conexeu Sciences Inc. For: 28 September By Investing.com - Investing.com Nigeria
Form 4 Conexeu Sciences Inc. For: 28 September By Investing.com - Investing.com South Africa
Form 4 Conexeu Sciences Inc. For: 28 September By Investing.com - Investing.com Australia
Form 4 Conexeu Sciences Inc. For: 28 September By Investing.com - Investing.com UK
At $0.001 a share, a Conexeu Sciences (CNXU) executive exercises rights to acquire stock. - stocktitan.net
Conexeu Sciences (NASDAQ:CNXU): What The Bearish Surge Signals? - Kalkine Media
Conexeu Sciences Revises Prospectus for 9.48 Million Shares with Latest Quarterly Report (NASDAQ: CNXU) - Kalkine Media
Conexeu (Nasdaq: CNXU) consultant gets 500K shares at $0.001; more hinge on FDA filing - Stock Titan
Conexeu Sciences (NASDAQ: CNXU) Reports $7.73M Quarterly Loss, Highlights Funding Challenges - Kalkine Media
CNXU 8-K FilingsCONEXEU SCIENCES INC SEC 8-K - Stock Titan
Conexeu Sciences Director Purcell Lynn Sebastian Executes 217,608-Share Deal at $2.30 Each - Kalkine Media
Conexeu Sciences (CNXU) director exercises 217K-share warrant at $2.30 - Stock Titan
Ambarella Q2 Revenue Rises 12% as Net Loss Narrows Sharply - minichart.com.sg
Investment fund caps Conexeu Sciences (CNXU) stake below 10% - Stock Titan
Near-10% stake in Conexeu (CNXU) tied to warrant cap - Stock Titan
Conexeu Sciences (NASDAQ:CNXU) Shares Down 5.2%Here's What Happened - marketbeat.com
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture - TradingView
Conexeu Steps Up Investor Outreach Ahead of Key Regulatory Milestones - TipRanks
Conexeu Sciences Sets September and October 2026 Conference Schedule - The Manila Times
At Nasdaq headquarters, a biotech company will present Sept. 9, then attend two more events. - Stock Titan
Conexeu Sciences (CNXU) pays consultants with $88K in stock - Stock Titan
Conexeu Sciences Inc.: Fundamental Analysis and Financial Ratings | CNXU | US20715F1003 - marketscreener.com
Here's Why We're Not Too Worried About Conexeu Sciences' (NASDAQ:CNXU) Cash Burn Situation - webull.com
The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts - Eastern Progress
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It. - The Spec
The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too. - marketscreener.com
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration - Moomoo
Jeffrey Sharpe Discloses Investment at Conexeu Sciences Inc. with 5.4% Stake - TradingView
2.3M-share stake in Conexeu Sciences (CNXU) revealed by single investor - Stock Titan
Conexeu (CNXU) director gets $0.001 warrants tied to Nasdaq, FDA goals - Stock Titan
CNXU - Finviz
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It. - GlobeNewswire
Conexeu Sciences Inc. (CNXU) BetaZacks.com - Zacks Investment Research
CNXU : Conexeu Sciences Inc. Key Company Details - Zacks Investment Research
Conexeu Sciences (CNXU) investor reports 12.3% stake and warrant-linked shares - Stock Titan
Conexeu Sciences Inc. (CNXU) investor discloses 5.5% stake in Schedule 13G filing - Stock Titan
OnePointTwo Capital Ventures (CNXU) discloses 1.88M-share Conexeu Sciences stake - Stock Titan
One Platform, Five Markets: Insights Into Conexeu Sciences Inc. - smallcapasia.com
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For - marketscreener.com
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For - GlobeNewswire
Conexeu to Present at 2026 Controversies & Conversations in Laser and Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration - marketscreener.com
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It - marketscreener.com
Conexeu Highlights ECM-Based Regenerative Platform Ahead of 2026 Aesthetics Symposium - TipRanks
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration - The Manila Times
Beyond volume: Conexeu to discuss the body's repair process - Stock Titan
Conexeu Sciences Ord Shs (CNXU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma’s TriKE® Program: Pipeline, Progress, & What’s Ahead - smallcapasia.com
Price to earnings forward of Conexeu Sciences Inc. – NASDAQ:CNXU - TradingView
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One - Investing News Network
Conexeu Sciences Inc Stock (CNXU) Financials Data
There is no financial data for Conexeu Sciences Inc (CNXU). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Conexeu Sciences Inc Stock (CNXU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sharpe Jeffrey Nathan | Director |
Sep 14 '26 |
Option Exercise |
0.00 |
500,000 |
500 |
1,500,000 |
| Purcell Lynn Sebastian | Director |
Jun 18 '26 |
Buy |
0.80 |
202,500 |
162,000 |
2,734,240 |
| Wright Michael G. | 10% Owner |
Jun 18 '26 |
Option Exercise |
0.00 |
250,000 |
250 |
2,148,048 |
| Wright Michael G. | 10% Owner |
May 26 '26 |
Option Exercise |
0.00 |
400,000 |
400 |
1,898,048 |
| Sharpe Jeffrey Nathan | Director |
May 22 '26 |
Option Exercise |
0.00 |
500,000 |
500 |
1,000,000 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):